Cancer Forums and News by PhD's

News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

Unraveling kidney cancer
By Dross at 2010-01-07 02:47

In a new study, scientists have searched for mutations in the gene regions of more than 100 kidney cancer samples, the largest number of samples from a single tumour type to be sequenced to date.

read more | 1 comment | 1584 reads

Cancer vaccine shows promise in patients with bowel, kidney and prostate cancer
By Dross at 2008-10-24 22:58

Geneva, Switzerland: Analysis of data from several phase I and II clinical trials of a new cancer vaccine has shown it is capable of eliciting an immune response in most patients with bowel, kidney and prostate cancer, and that it may provide clinical benefit.

In a news briefing at the 20th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva yesterday (Thursday 23 October), Dr Richard Harrop, vice-president of clinical immunology at Oxford BioMedica, a UK-based biotechnology company – said: "Our exploratory analyses of data from nine different trials of TroVax® demonstrate significant associations between immune responses and overall survival in patients with colorectal cancer, renal cancer and prostate cancer.

read more | 2439 reads

How less can be more when treating some juvenile kidney cancers
By Dross at 2008-01-10 02:19

ROCHESTER, Minn. -- A new Mayo Clinic study suggests that removing the entire kidney from younger patients with small kidney tumors may lead to decreased overall survival compared with an operation that removes the tumor but leaves the kidney intact. The study will be published in the February issue of the Journal of Urology.

Radical nephrectomy is a surgical procedure to remove the entire kidney along with the adrenal glandterm that sits atop the kidney and adjacent lymph nodes. In a partial nephrectomy, only the tumor is removed, sparing the surrounding normal kidney tissue.

“For patients with small kidney tumors, removal of the entire kidney may be associated with long-term consequences that we did not previously recognize when compared to removal of just the tumor,” says the study’s lead author, R. Houston Thompson, M.D., a Mayo Clinic urologist currently serving a fellowship at Memorial Sloan-Kettering Cancer Center. “Recent evidence suggests that there is a graded impact on survival based on declining overall kidney function. So as kidney function declines, the risk of heart attacks and heart-related events goes up, and consequently the risk of death from these events goes up.”

read more | 1827 reads

Cryoablation continues to show good results for kidney cancer patients
By Dross at 2007-11-26 21:01

OCHESTER, Minn. -- A review of 62 Mayo Clinic patients who underwent cryoablation to treat cancerous kidney tumors shows that the patients are cancer free for up to two and a half years after having had the procedure.

Also called cryotherapyterm or cryosurgery, cryoablation is a procedure in which extreme cold is applied to the tumor using a cryoprobe, a hollow needle-like device filled with argon gas. The gas rapidly freezes the targeted tumor.

As this study and others continue to show, cryoablation appears to be an effective treatment for cancerous kidney tumors. But researchers caution that at this time, it be used only for patients who are not candidates for surgery, because follow-up studies are needed before the procedure can be widely applied, states Thomas Atwell, M.D., a Mayo Clinic radiologist and the study's primary investigator.

read more | 1759 reads

First Multiple Drug Trial to Attack Blood Vessel Formation in Kidney Cancer
By Dross at 2007-10-03 23:49

PHILADELPHIA – In the first clinical trial of its kind, researchers at the University of Pennsylvania School of Medicine and the Abramson Cancer Center will lead a nationwide test of anti-cancer drug combinations that target blood vessel growth in patients with advanced kidney cancer. The trial is being conducted with colleagues in the Eastern Cooperative Oncology Group, a network of researchers, physicians, and health care professionals at public and private institutions.

read more | 3 comments | 2508 reads

Glowing dye improves cancer removal in kidney
By Dross at 2007-06-07 08:37

A new way to provide clear images of cancerous tumors in the kidney during surgery promises to help physicians preserve as much kidney function as possible while still removing all the malignant tissue – a significant advance as doctors discover that saving as much healthy kidney tissue as possible is crucial for the future health of cancer patients.

Results from a small pilot study were presented at the recent American Urological Association’s annual meeting, giving surgeons a sneak peek at a new imaging process that gives healthy kidney tissue a fluorescent glow, clearly differentiating it from cancerous tissue. This glow assists surgeons in the accurate removal of cancerous tissue during a partial nephrectomy, or the removal of a portion of the kidney.

read more | 1957 reads

HHMI News: Kidney Cancer Shuts Down Protein Destruction Complex
By Dross at 2007-05-21 22:20

Kidney Cancer Shuts Down Protein Destruction Complex


New evidence shows that Wilms tumor - a rare kidney cancer that affects children - promotes its own growth agenda by taking over a genetic program used by normal cells during development. The studies demonstrate that Wilms tumor exploits the same signaling pathway that is targeted by colorectal cancer cells, but it goes about hijacking that pathway in an entirely different way. The finding suggests that drugs targeting this pathway may be effective against a variety of cancers.

read more | 2373 reads

Translocation Kidney Cancer after Chemotherapy in Childhood
By Dross at 2007-04-22 22:28

This article out of Johns Hopkins reviewed the risk of renal cell carcinomaterm occurring as a secondary malignancy after chemotherapyterm in childhood. It is known that children who survive cancer are at the risk of developing another malignancy 20 times more likely than the general population. This study described the clinical, pathologic, cytogenetic, and molecular data on six translocation renal cell carcinomas that arose in five patients who had received chemotherapy.

At the time of diagnosis, the children were between the ages of 6-22 years. Histologically, the tumor showed typical features that are described for translocation renal cell carcinomas. At the molecular level, three of the tumors contained the ASPL-TFE3 fusion; two contained Alpha-TFEB and one contained PRCC-TFE3. The time span between chemotherapy and the diagnosis of these renal cell carcinomas ranged from 4-13 years. The indications varied and including acute promyelocytic leukemiaterm, acute myeloid leukemia, bilateral Wilms' tumor, systemic lupus erythematosus, and a conditioning regimen of bone marrow transplantation secondary to Hurler's syndrome. This latter patient also received radiation.

read more | 3775 reads

Cryoablation -- A new treatment option for some kidney tumor patients
By Dross at 2007-03-28 22:38

Mayo Clinic researchers report that freezing kidney tumors through percutaneous cryoablation shows promise for patients who are not good candidates for surgery. Their early findings showing short-term success in more than 90 percent of selected patients are published in this month’s issue of Radiology.

The standard treatment for kidney tumors is surgery, providing a high likelihood of a long-term cure. For some patients, surgery is not an option, and Mayo’s urologists and radiologists collaborated to find alternatives for these individuals. If these patients are frail due to age or illness or are not able to have surgery because of other factors, percutaneous cryoablation may be an option.

read more | 2 comments | 1944 reads

Basque Research
By Dross at 2007-03-01 23:40

Research has shown the efficacy of a pharmaceutical drug known as sunitinibterm which halts progress of metastaticterm kidney cancer. The work was published recently in the prestigious international medical journal, The New England Journal of Medicine and involved medical co-researchers from the Oncology Department of the University Hospital of Navarra, in collaboration with the Clinical Trials Area of the same Department. To date the usual treatment for kidney cancer of a metastatic nature has been based solely on immunotherapy. In phase III of the research sunitinib was compared with interferon (a type of immunotherapy) in 750 patients with metastatic kidney cancer and it was shown that sunitinib is more efficient in halting the progress of the disease. 101 medical centres from all over the world took part in the research. Given the short period of follow-up in the research, the effect of the treatment on survival rates could not be corroborated. Although, in general, the treatment is well tolerated, certain side effectsterm can occur and have to be taken into consideration - hypothyroidism, high blood pressure and fatigue. Metastatic kidney cancer is one of the cancer pathologies the treatment of which has made least progress in recent years. The usual treatment with immunotherapy had not shown clearly positive results in many patients. Sunitinib is one of the few pharmaceutical drugs that provide clear improvements in this type of cancer. The mechanism of functioning of sunitinib is in blocking the generation of new blood vessels. Tumours, in order to grow, need to develop blood vessels and this pharmaceutical drug impedes their growth, blocking a factor known as VEGFterm, and other similar ones, which stimulate vascular growth. The use of sunitinib in Spain is to be approved shortly for the treatment of kidney cancer with metastasistermterm although, at the University Hospital, it has been employed with over 40 patients for the last two years, using clinical trials.

read more | 2466 reads

Kidney Cancer Basics
By Dross at 2007-02-19 06:48

Definition of kidney cancer: Cancer that forms in tissues of the kidneys. Kidney cancer includes renal cell carcinomaterm (cancer that forms in the lining of very small tubes in the kidney that filter the blood and remove waste products) and renal pelvis carcinoma (cancer that forms in the center of the kidney where urine collects). It also includes Wilms' tumor, which is a type of kidney cancer that usually develops in children under the age of 5.

Estimated new cases and deaths from kidney (renal cell and renal pelvis) cancer in the United States in 2007:

New cases: 51,190
Deaths: 12,890


read more | 8615 reads

New Study Seeks Better Outcomes for Kidney Cancer
By Dross at 2007-02-06 02:37




A new clinical trial at the Ohio State University Medical Center’s James Cancer Hospital and Solove Research Institute will investigate the safety and toxicity of a new combination of drugs for treating kidney cancer.


The phase-I study combines high-dose interleukin-2 with the drug sorafenibterm and will enroll up to 24 patients.

read more | 2 comments | 2132 reads

Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
By Dross at 2007-01-12 05:44



Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. today announced that the New England Journal of Medicine has published their pivotal Phase III trial demonstrating that Nexavartermterm (sorafenibterm) tablets doubled median progression-free survival (PFS) in patients with advanced renal cell carcinomaterm (RCC), or kidney cancer. The data, as assessed by independent radiologic review, are from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) the largest randomized controlled trial ever conducted in advanced RCC. "Historically, patients with kidney cancer have had limited treatment options and there has been a particularly critical need for new therapies to help patients with advanced disease," said co-principal investigator Ronald Bukowski, M.D., Director of the Experimental Therapeutics Program of The Cleveland Clinic Taussig Cancer Center in Cleveland, OH. "This landmark study demonstrated the efficacy, tolerability and clinical benefit of Nexavar, which has rapidly become a valuable weapon against this devastating disease." Based on these data, Nexavar was granted U.S. Food and Drug Administration (FDA) approval for the treatment of patients with advanced RCC, or kidney cancer, on December 20, 2005. Since then, Nexavar has been approved in nearly 50 countries. "Nexavar was the first new drug approved for patients with advanced kidney cancer in over a decade," said Bill Bro, President and Chief Executive Officer of the Kidney Cancer Association (KCA). "With the advent of targeted therapies such as Nexavar, there has been remarkable change patients are experiencing improved outcomes without the toxic effects traditionally associated with chemotherapyterm."

read more | 2131 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 04:52 PM.